Document ID: chunk:federal_register_of_legislation:F2025C00039:reg:73437
Version: federal_register_of_legislation:F2025C00039
Segment Type: reg
Provision Reference: reg 73437
Character Range: 23278–24669

73437              A nucleic acid‑based multi‑gene panel test of tumour tissue from a patient with a new diagnosis of non‑small cell lung cancer requested by, or on behalf of, a specialist or consultant physician, if the test is:                                                                                                                                                                                                                                                                                                                                                                                                                                         1,247.00
                     (a) to detect variants in at least EGFR, BRAF, KRAS and MET exon 14 to determine access to specific therapies relevant to these variants listed on the Pharmaceutical Benefits Scheme (PBS); and
                     (b) to detect the fusion status of at least ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3; and
                       (i) to determine access to specific therapies relevant to these variants listed on the PBS; or
                       (ii) determine if the requirements relating to EGFR, ALK and ROS1 status for access immunotherapies listed on the PBS are fulfilled; and
                     (c) not associated with a service to which item 73438, 73439, 73337, 73341, 73344, 73436 or 73351 applies